BACKGROUND: Diffusion-tensor (DT) magnetic resonance imaging (MRI) has the potential to elucidate some characteristics of tissue microstructure inaccessible to other MRI techniques. OBJECTIVE: To investigate whether normal-appearing brain tissue abnormalities occur in patients with multiple sclerosis at the earliest clinical stage and whether their severity is predictive of a short-term disease evolution by using DT MRI. DESIGN: Forty-five patients and 22 healthy control subjects were studied. All patients had had a clinically isolated syndrome within the 3 months preceding study enrollment and paraclinical evidence of disease dissemination in space. During a single session, dual-echo, pulsed-gradient spin-echo echo-planar, and postgadolinium T1-weighted images of the brain were obtained from each subject. In patients, dual-echo and enhanced images were obtained after 3 and 12 months, to detect MRI signs of disease dissemination in time. An on-study neurological examination was also conducted to ascertain the occurrence of clinical relapses. Mean diffusivity and fractional anisotropy maps were derived from DT images. Normal-appearing white matter (NAWM) and normal-appearing gray matter mean diffusivity and fractional anisotropy histograms were produced and analyzed. RESULTS: During the study period, 29 patients showed MRI evidence of disease dissemination in time. When compared with healthy controls, patients showed higher average NAWM mean diffusivity (P = .01), lower average NAWM mean diffusivity peak height (P < .001), and fractional anisotropy (P < .001). The DT MRI characteristics of patients did not differ between those with and those without disease dissemination in time at follow-up. CONCLUSIONS: In patients with multiple sclerosis at the earliest clinical stage, the severity of NAWM damage does not predict new lesion formation in the short term, suggesting that the "diffuse" component of tissue damage is, at least partially, independent of the "discrete," predominantly inflammatory aspects of the disease since its clinical onset.
BACKGROUND: Diffusion-tensor (DT) magnetic resonance imaging (MRI) has the potential to elucidate some characteristics of tissue microstructure inaccessible to other MRI techniques. OBJECTIVE: To investigate whether normal-appearing brain tissue abnormalities occur in patients with multiple sclerosis at the earliest clinical stage and whether their severity is predictive of a short-term disease evolution by using DT MRI. DESIGN: Forty-five patients and 22 healthy control subjects were studied. All patients had had a clinically isolated syndrome within the 3 months preceding study enrollment and paraclinical evidence of disease dissemination in space. During a single session, dual-echo, pulsed-gradient spin-echo echo-planar, and postgadolinium T1-weighted images of the brain were obtained from each subject. In patients, dual-echo and enhanced images were obtained after 3 and 12 months, to detect MRI signs of disease dissemination in time. An on-study neurological examination was also conducted to ascertain the occurrence of clinical relapses. Mean diffusivity and fractional anisotropy maps were derived from DT images. Normal-appearing white matter (NAWM) and normal-appearing gray matter mean diffusivity and fractional anisotropy histograms were produced and analyzed. RESULTS: During the study period, 29 patients showed MRI evidence of disease dissemination in time. When compared with healthy controls, patients showed higher average NAWM mean diffusivity (P = .01), lower average NAWM mean diffusivity peak height (P < .001), and fractional anisotropy (P < .001). The DT MRI characteristics of patients did not differ between those with and those without disease dissemination in time at follow-up. CONCLUSIONS: In patients with multiple sclerosis at the earliest clinical stage, the severity of NAWM damage does not predict new lesion formation in the short term, suggesting that the "diffuse" component of tissue damage is, at least partially, independent of the "discrete," predominantly inflammatory aspects of the disease since its clinical onset.
Authors: F G Garaci; V Colangelo; A Ludovici; F Gaudiello; S Marziali; D Centonze; L Boffa; G Simonetti; R Floris Journal: AJNR Am J Neuroradiol Date: 2007-03 Impact factor: 3.825
Authors: Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman Journal: Drugs Date: 2008 Impact factor: 9.546
Authors: Waqar Rashid; Andreas Hadjiprocopis; Gerard Davies; Collette Griffin; Declan Chard; Michaela Tiberio; Dan Altmann; Claudia Wheeler-Kingshott; Dan Tozer; Alan Thompson; David H Miller Journal: J Neurol Date: 2008-03-20 Impact factor: 4.849
Authors: Joshua S Shimony; Yvette I Sheline; Gina D'Angelo; Adrian A Epstein; Tammie L S Benzinger; Mark A Mintun; Robert C McKinstry; Abraham Z Snyder Journal: Biol Psychiatry Date: 2009-04-17 Impact factor: 13.382
Authors: Andrew W Varga; Glyn Johnson; James S Babb; Joseph Herbert; Robert I Grossman; Matilde Inglese Journal: J Neurol Sci Date: 2009-01-31 Impact factor: 3.181